Brokerages Expect Curis, Inc. (CRIS) Will Post Quarterly Sales of $2.17 Million

Brokerages expect Curis, Inc. (NASDAQ:CRIS) to report sales of $2.17 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Curis’ earnings. The lowest sales estimate is $2.03 million and the highest is $2.30 million. Curis posted sales of $1.76 million during the same quarter last year, which would indicate a positive year over year growth rate of 23.3%. The business is scheduled to issue its next earnings report on Thursday, November 2nd.

According to Zacks, analysts expect that Curis will report full-year sales of $2.17 million for the current financial year, with estimates ranging from $8.26 million to $8.50 million. For the next year, analysts anticipate that the firm will report sales of $9.47 million per share, with estimates ranging from $8.54 million to $10.40 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Curis.

Curis (NASDAQ:CRIS) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. The firm had revenue of $2.10 million during the quarter, compared to analyst estimates of $2.08 million. During the same period in the previous year, the company posted ($0.09) EPS. Curis’s revenue for the quarter was up 23.5% compared to the same quarter last year.

A number of equities research analysts have issued reports on the stock. ValuEngine cut shares of Curis from a “hold” rating to a “sell” rating in a report on Friday, September 15th. BidaskClub cut shares of Curis from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, Zacks Investment Research raised shares of Curis from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Three equities research analysts have rated the stock with a sell rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $6.00.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/10/13/brokerages-expect-curis-inc-cris-will-post-quarterly-sales-of-2-17-million.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CRIS. Point72 Asset Management L.P. purchased a new position in shares of Curis during the 1st quarter valued at $1,391,000. Perceptive Advisors LLC purchased a new position in shares of Curis during the 1st quarter valued at $1,390,000. FMR LLC grew its position in shares of Curis by 2.7% during the 1st quarter. FMR LLC now owns 15,131,961 shares of the biotechnology company’s stock valued at $42,067,000 after purchasing an additional 393,582 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Curis by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 4,827,625 shares of the biotechnology company’s stock valued at $13,421,000 after purchasing an additional 304,268 shares in the last quarter. Finally, State Street Corp grew its position in shares of Curis by 10.4% during the 2nd quarter. State Street Corp now owns 1,857,044 shares of the biotechnology company’s stock valued at $3,511,000 after purchasing an additional 175,424 shares in the last quarter. Hedge funds and other institutional investors own 44.72% of the company’s stock.

Curis (NASDAQ:CRIS) traded down 3.03% during trading on Tuesday, hitting $1.60. The stock had a trading volume of 852,569 shares. The firm has a 50 day moving average price of $1.76 and a 200-day moving average price of $1.98. The firm’s market capitalization is $230.20 million. Curis has a 1-year low of $1.47 and a 1-year high of $3.72.

About Curis

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Get a free copy of the Zacks research report on Curis (CRIS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply